|
1.
|
|
10 p, 889.8 KB |
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
/
Prat, A. (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Lluch, Ana (Hospital Clínic Universitari (València)) ;
Albanell Mestres, Joan (Universitat Pompeu Fabra) ;
Barry, W. T. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Biostatistics and Computational Biology) ;
Fan, C. (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Chacón, José Ignacio (Hospital Virgen de la Salud (Toledo)) ;
Parker, J. S. (University of North Carolina. Department of Genetics) ;
Calvo, L.. (Complejo Hospitalario Universitario de A Coruña) ;
Plazaola, A. (Department of Medical Oncology, Onkologikoa) ;
Arcusa, Àngels (Consorci Sanitari de Terrassa. Departament d'Oncologia Mèdica) ;
Seguí-Palmer, M. A. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Burgués, Octavio (Hospital Clínic Universitari (València)) ;
Ribelles, Nuria (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Rodriguez-Lescure, A. (Hospital General Universitario de Elche) ;
Guerrero, A. (Fundació Institut Valencià d'Oncologia) ;
Ruiz-Borrego, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Munárriz, Blanca (Hospital Universitari i Politècnic La Fe (València)) ;
López, J. A. (Hospital San Camilo) ;
Adamo, Barbara (Hospital Universitari Vall d'Hebron) ;
Cheang, M. C. U. (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Li, Y (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Hu, Z. (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Gulley, M. L. (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Vidal, M. J. (Hospital Universitari Vall d'Hebron) ;
Pitcher, B. N. (Alliance Statistical and Data Center, Duke University) ;
Liu, M. C. (Mayo Clinic. Department of Oncology) ;
Citron, M. L. (ProHEALTH Care Associates, LLP) ;
Ellis, M. J. (Washington University. Department of Oncology) ;
Mardis, E. (Washington University. Department of Oncology) ;
Vickery, T. (Washington University. Department of Oncology) ;
Hudis, C. A. (Memorial Sloan Kettering Cancer Center) ;
Winer, E. P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Carey, L. A. (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Caballero, Rosalía (Grupo Español de Investigación en Cáncer de Mama) ;
Carrasco, E. (Grupo Español de Investigación en Cáncer de Mama) ;
Martín, M. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Perou, Charles M. (University of North Carolina. Department of Pathology and Laboratory Medicine) ;
Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. [...]
2014 -  10.1038/bjc.2014.444
British Journal of Cancer, Vol. 111 (08 2014) , p. 1532-1541
|
|
|
2.
|
|
12 p, 915.6 KB |
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
/
Bastien, Roy R. L. (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Rodríguez-Lescure, Álvaro (Hospital General Universitario de Elche) ;
Ebbert, Mark T. W. (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Prat, Aleix (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Munárriz, Blanca (Hospital Universitari i Politècnic La Fe (València)) ;
Rowe, Leslie (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Miller, Patricia (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Ruiz Borrego, Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Anderson, Daniel (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Lyons, Bradley (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Álvarez López, Isabel (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Dowell, Tracy (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Wall, David (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Seguí, Miguel Ángel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Barley, Lee (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Boucher, Kenneth M. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Alba, Emilio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Pappas, Lisa (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Davis, Carole A. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Aranda, Ignacio (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Fauron, Christiane (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Stijleman, Inge J. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Palacios, José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Antón, Antonio (Hospital Universitario Miguel Servet (Saragossa)) ;
Carrasco, Eva (GEICAM. Spanish Breast Cancer Research Group (Madrid)) ;
Caballero, Rosalía (GEICAM. Spanish Breast Cancer Research Group (Madrid)) ;
Ellis, Matthew J. (Washington University. Department of Oncology (St. Louis, Estats Units d'Amèrica)) ;
Nielsen, Torsten O. (University of British Columbia. Department of Anatomical Pathology (Vancouver, Canadà)) ;
Perou, Charles M. (University of North Carolina at Chapel Hill. Lineberger Comprehensive Cancer Center (Chapel Hill, Estats Units d'Amèrica)) ;
Astill, Mark (The ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, Estats Units d'Amèrica)) ;
Bernard, Philip S. (Huntsman Cancer Institute (Salt Lake City, Estats Units d'Amèrica)) ;
Martín Jiménez, Miguel (Hospital General Universitario Gregorio Marañón)
Background: Many methodologies have been used in research to identify the "intrinsic" subtypes of breast cancer commonly known as Luminal A, Luminal B, HER2-Enriched (HER2-E) and Basal-like. The PAM50 gene set is often used for gene expression-based subtyping; however, surrogate subtyping using panels of immunohistochemical (IHC) markers are still widely used clinically. [...]
2012 - 10.1186/1755-8794-5-44
BMC medical genomics, Vol. 15, N. 44 (October 2012) , p. 1-9
4 documents
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
